901P - The impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors: A meta-analysis

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cytotoxic agents
Ovarian Cancer
Therapy
Biological therapy
Presenter Ines Monteiro Vasconcelos
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors I. Monteiro Vasconcelos1, J. Olschewski2, I. Braicu1, J. Sehouli1
  • 1Gynecology Department, Charité Campus Virchow, 13353 - Berlin/DE
  • 2Gynecology, Charité, 13353 - Berlin/DE

Abstract

Aim

Background: Treatment of borderline ovarian tumors (BOT) remains contentious. Regarding invasive implants, there is no consensus regarding therapy. This article evaluates the benefits of platinum-based adjuvant treatment in patients with BOT.

Methods

Methods: The PubMed and Cochrane Library databases were systematically searched for articles using the terms ((Borderline) OR (low malignant potential) AND (ovarian)) AND ((tumor) OR (cancer)) AND ((follow-up) OR (survival) OR (treatment) OR (chemotherapy) OR (adjuvant treatment)).

Results

Results: We identified 31 articles including 4982 patients. Together 623 patients presented non-invasive-, 184 invasive- and 91 unspecified implants. Central pathological examination was performed in 23 studies. Nine studies included more than 90% stage I patients, while 10 included only advanced stage patients. Nineteen studies reported patients undergoing complete cytoreduction, 10 reported response rates and 9 compared survival outcomes. All studies provided information regarding either mortality or recurrence rates. A meta-analysis of the 13 studies providing separate mortality data for both treatment groups, including 2206 women, favored surgical treatment only (OR = 7,44 95%CI = 3,39-16,32; p < 0,0005). Regarding survival data 4 studies reported no difference between groups. In the adjuvant setting, 4 reported worse outcome and 1 reported a non-significant trend to worse outcome. We were unable to pool the results of all the included studies, as not all studies report the needed data.

Conclusions

Conclusions: We do not find evidence supporting platinum-based adjuvant therapy for BOT, including in patients with invasive implants. Nonetheless, it's likely that the small sub-group of patients relapsing as high-grade ovarian carcinoma will profit from adjuvant treatment.

Disclosure

All authors have declared no conflicts of interest.